All cancers excluding non-melanoma skin cancer, malignant (ICD10 C00-C97 excluding C44)

NB: changes in survival over time for all cancers (combined) may reflect changes in the relative frequency of different cancer types

(of different average prognosis) as well as changes in early detection or treatment effectiveness for specific cancers.

Five-year relative survival by diagnosis year and age at diagnosis: combined sexes

	Five-year relative survival (with 95% confidence interval) by diagnosis year
Age at diagnosis	1994-97	1998-2002	2003-2007	2007-2009
	cohort	cohort	cohort	*hybrid

all 15-99	45.7%	51.8%	59.5%	60.2%
(unstandardized)	(45.1-46.2%)	(51.3-52.2%)	(58.9-60.0%)	(59.6-60.7%)

all 15-99	44.0%	49.6%	56.4%	57.0%
(age-standardized)#	(42.8-45.1%)	(48.6-50.5%)	(55.3-57.4%)	(55.8-58.0%)

15-44	68.3%	74.2%	79.3%	80.8%
	(66.8-69.6%)	(73.0-75.3%)	(78.0-80.4%)	(79.5-82.0%)

45-54	56.4%	62.3%	69.5%	70.6%
	(54.9-57.6%)	(61.1-63.3%)	(68.2-70.6%)	(69.3-71.8%)

55-64	46.6%	55.2%	63.1%	63.8%
	(45.4-47.6%)	(54.2-56.0%)	(62.1-64%)	(62.7-64.8%)

65-74	38.8%	45.9%	55.1%	55.6%
	(37.8-39.7%)	(45.0-46.6%)	(54.1-56.0%)	(54.5-56.6%)

75-99	36.2%	37.6%	41.5%	41.5%
	(34.9-37.3%)	(36.5-38.5%)	(40.2-42.7%)	(40.2-42.7%)

Five-year relative survival by diagnosis year and age at diagnosis: men

	Five-year relative survival (with 95% confidence interval) by diagnosis year				EUROCARE-4	EUROCARE-4
Age at diagnosis	1994-97	1998-2002	2003-2007	2007-2009	##2000-2002	##2000-2002
	cohort	cohort	cohort	*hybrid	Ireland	Europe average

all 15-99	39.9%	48.1%	58.5%	59.2%
(unstandardized)	(39.1-40.6%)	(47.4-48.7%)	(57.7-59.2%)	(58.4-59.9%)

all 15-99	39.6%	47.1%	56.6%	57.4%	48.1%	47.3%
(age-standardized)#	(37.9-41.1%)	(45.7-48.4%)	(55.0-58.1%)	(55.7-59.0%)	(47.2-49.0%)	(46.8-47.8%)

15-44	62.5%	70.7%	76.6%	79.3%
	(60.0-64.9%)	(68.7-72.5%)	(74.5-78.5%)	(77.0-81.2%)

45-54	41.5%	49.1%	60.6%	62.0%
	(39.2-43.6%)	(47.2-50.9%)	(58.6-62.5%)	(59.7-64.0%)

55-64	38.9%	50.2%	61.9%	62.5%
	(37.3-40.3%)	(48.9-51.5%)	(60.5-63.1%)	(61.0-63.8%)

65-74	36.6%	46.4%	57.4%	58.3%
	(35.3-37.8%)	(45.2-47.4%)	(56.1-58.6%)	(56.8-59.6%)

75-99	36.7%	38.8%	45.2%	45.4%
	(35.0-38.4%)	(37.3-40.2%)	(43.3-47%)	(43.5-47.3%)

Five-year relative survival by diagnosis year and age at diagnosis: women

	Five-year relative survival (with 95% confidence interval) by diagnosis year				EUROCARE-4	EUROCARE-4
Age at diagnosis	1994-97	1998-2002	2003-2007	2007-2009	##2000-2002	##2000-2002
	cohort	cohort	cohort	*hybrid	Ireland	Europe average

all 15-99	51.2%	55.4%	60.5%	61.1%
(unstandardized)	(50.4-51.9%)	(54.7-56.0%)	(59.7-61.2%)	(60.3-61.9%)

all 15-99	47.8%	51.4%	55.5%	55.8%	51.9%	55.8%
(age-standardized)#	(46.2-49.3%)	(50.0-52.6%)	(54-56.9%)	(54.2-57.4%)	(51.0-52.8%)	(55.3-56.2%)

15-44	71.7%	76.5%	80.9%	81.8%
	(69.9-73.4%)	(75.0-77.8%)	(79.3-82.3%)	(80.1-83.3%)

45-54	65.7%	70.7%	75.2%	76.4%
	(64.0-67.3%)	(69.3-72.0%)	(73.7-76.6%)	(74.8-77.8%)

55-64	54.6%	60.4%	64.5%	65.4%
	(53-56.1%)	(59.1-61.6%)	(63.1-65.8%)	(63.8-66.9%)

65-74	41.5%	45.2%	51.6%	51.6%
	(40.1-42.9%)	(43.9-46.4%)	(50.0-53.0%)	(49.9-53.1%)

75-99	35.6%	36.4%	38.0%	37.7%
	(33.9-37.2%)	(35.0-37.7%)	(36.4-39.6%)	(36.0-39.4%)

Footnotes:

*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period,

supplemented by follow-up 2005-2009 for cases diagnosed in 2005 or 2006 (to provide more reliable estimation of the first two years of survival).

In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data.

# Age-standardized figures use the standard patient population proposed for this cancer grouping by:

Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316.

(Population weights = age 15-44 x7000, 45-54 x12000, 55-64 x23000, 65-74 x29000, 75-99 x29000)

## For comparison, the age-standardized average survival (2000-2002) is quoted for countries (including Ireland) that participated in the EUROCARE-4 study:

Verdecchia A., Francisci S., Brenner H., et al. 2007. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796.

Exclusions (as in EUROCARE):

Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient

(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour.

Cancer registration is a dynamic process and information is continually updated on our database.

As a result, the figures given here may not correspond exactly to those in previous reports or to those previously shown on our website.